Marc W Deyell1, Steve Doucette2, Ratika Parkash2, Isabelle Nault3, Lorne Gula4, Christopher Gray2, Martin Gardner2, Laurence D Sterns5, Jeff S Healey6, Vidal Essebag7, John L Sapp2. 1. Division of Cardiology, Department of Medicine, Heart Rhythm Services and Centre for Cardiovascular Innovation, University of British Columbia, St. Paul's Hospital, #200-1033 Davie Street, Vancouver, British Columbia V6E 1M7, Canada. 2. Department of Medicine, QEII Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, Canada. 3. Department of Medicine, Université Laval, Québec City, Québec, Canada. 4. Department of Medicine, Western University, London, Ontario, Canada. 5. Department of Medicine, Royal Jubilee Hospital, Victoria, British Columbia, Canada. 6. Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada. 7. Department of Medicine, McGill University Health Centre and Hôpital Sacré-Coeur de Montréal, Montreal, Québec, Canada.
Abstract
AIMS: Catheter ablation is superior to escalated antiarrhythmic drugs among patients with ventricular tachycardia (VT) and prior myocardial infarction (MI). However, it is uncertain whether clinical VT characteristics, should influence choice of therapy. The purpose of this study was to evaluate whether presentation with electrical storm and the clinical VT cycle length predicted response to ablation vs. escalated antiarrhythmic therapy. METHODS AND RESULTS: All patients enrolled in the Ventricular Tachycardia Ablation vs. Escalated Antiarrhythmic Drug Therapy in Ischaemic Heart Disease (VANISH) trial were included. The association between VT cycle length and presentation with electrical storm and the primary outcome of death, subsequent VT storm or appropriate ICD shock was evaluated. Among the study population of 259 patients, escalated antiarrhythmic drug therapy had worse outcomes for those presenting with a VT cycle length >400 ms [<150 b.p.m., 89/259, hazard ratio (HR) 1.7 (1.02-3.13)]. This effect was more pronounced among those taking amiodarone at baseline [HR of 2.22 (1.19-4.16)]. Presentation with VT storm (32/259) did not affect the primary outcome between groups. However, those presenting with VT storm on amiodarone had a trend towards worse outcomes with escalated antiarrhythmic therapy [HR 4.31 (0.55-33.93)]. CONCLUSION: The VT cycle length can influence response to either ablation or escalated drug therapy in patients with VT and prior MI. Those with slow VT had improved outcomes with ablation. Patients presenting with electrical storm demonstrated similar outcomes to the overall trial population, with a trend to benefit of catheter ablation, particularly in those on amiodarone. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Catheter ablation is superior to escalated antiarrhythmic drugs among patients with ventricular tachycardia (VT) and prior myocardial infarction (MI). However, it is uncertain whether clinical VT characteristics, should influence choice of therapy. The purpose of this study was to evaluate whether presentation with electrical storm and the clinical VT cycle length predicted response to ablation vs. escalated antiarrhythmic therapy. METHODS AND RESULTS: All patients enrolled in the Ventricular Tachycardia Ablation vs. Escalated Antiarrhythmic Drug Therapy in Ischaemic Heart Disease (VANISH) trial were included. The association between VT cycle length and presentation with electrical storm and the primary outcome of death, subsequent VT storm or appropriate ICD shock was evaluated. Among the study population of 259 patients, escalated antiarrhythmic drug therapy had worse outcomes for those presenting with a VT cycle length >400 ms [<150 b.p.m., 89/259, hazard ratio (HR) 1.7 (1.02-3.13)]. This effect was more pronounced among those taking amiodarone at baseline [HR of 2.22 (1.19-4.16)]. Presentation with VT storm (32/259) did not affect the primary outcome between groups. However, those presenting with VT storm on amiodarone had a trend towards worse outcomes with escalated antiarrhythmic therapy [HR 4.31 (0.55-33.93)]. CONCLUSION: The VT cycle length can influence response to either ablation or escalated drug therapy in patients with VT and prior MI. Those with slow VT had improved outcomes with ablation. Patients presenting with electrical storm demonstrated similar outcomes to the overall trial population, with a trend to benefit of catheter ablation, particularly in those on amiodarone. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Takuro Nishimura; Gaurav A Upadhyay; Zaid A Aziz; Andrew D Beaser; Dalise Y Shatz; Hemal M Nayak; Roderick Tung Journal: Circulation Date: 2020-11-10 Impact factor: 29.690
Authors: Pasquale Vergara; Roderick Tung; Marmar Vaseghi; Chiara Brombin; David S Frankel; Luigi Di Biase; Koichi Nagashima; Usha Tedrow; Wendy S Tzou; William H Sauer; Nilesh Mathuria; Shiro Nakahara; Kairav Vakil; Venkat Tholakanahalli; T Jared Bunch; J Peter Weiss; Timm Dickfeld; Rama Vunnam; Dhanunjaya Lakireddy; J David Burkhardt; Anna Correra; Pasquale Santangeli; David Callans; Andrea Natale; Francis Marchlinski; William G Stevenson; Kalyanam Shivkumar; Paolo Della Bella Journal: Heart Rhythm Date: 2017-08-24 Impact factor: 6.343
Authors: H Calkins; A Epstein; D Packer; A M Arria; J Hummel; D M Gilligan; J Trusso; M Carlson; R Luceri; H Kopelman; D Wilber; J M Wharton; W Stevenson Journal: J Am Coll Cardiol Date: 2000-06 Impact factor: 24.094
Authors: Saurabh Kumar; Akira Fujii; Sunil Kapur; Jorge Romero; Nishaki K Mehta; Shinichi Tanigawa; Laurence M Epstein; Bruce A Koplan; Gregory F Michaud; Roy M John; William G Stevenson; Usha B Tedrow Journal: J Cardiovasc Electrophysiol Date: 2016-11-29
Authors: Marketa Kozeluhova; Petr Peichl; Robert Cihak; Dan Wichterle; Vlastimil Vancura; Jan Bytesnik; Josef Kautzner Journal: Europace Date: 2010-10-14 Impact factor: 5.214